Acetyl-L-Carnitine for Cognitive Function

Verdict: Weak, inconsistent evidence for cognition

Acetyl-L-carnitine shows only a small, unreliable benefit in people with mild cognitive impairment or early Alzheimer's disease, and no measurable effect in cognitively healthy adults. It is not a proven way to boost memory or focus.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The grade stays weak because the clinical signal is small and does not survive objective testing. The pivotal 2003 meta-analysis (PMID 12598816), pooling 21 RCTs in 1,204 people with mild cognitive impairment or mild Alzheimer's disease, found only a small advantage over placebo (effect size ~0.20). Its trials are old, heterogeneous, and of undisclosed funding, with many sponsored by manufacturers during that era.

A Cochrane review from the same year (PMID 12804452) found a benefit only on the subjective Clinical Global Impression scale, none on objective cognitive or functional outcomes, and explicitly advised against routine clinical use for dementia. A 2020 critical update (PMID 32408706) concluded results across trials remain inconsistent and that the role of acetyl-L-carnitine is still under debate.

For the healthy users targeted by 'brain and memory' marketing, a 2017 Cochrane review (PMID 28349514, ~200 analysable participants) found no measurable effect on reaction time, vigilance, or memory, on very-low-quality evidence. Regulators reinforce this: EFSA formally rejected the cognitive-function health claim for lack of a cause-and-effect relationship, the US FDA treats carnitine only as a nutrient supplement, the WHO does not list it, and no major clinic (Mayo, Cleveland, Harvard) endorses it for cognition.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.47
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
82%
Highly consistent evidence
Evidence level
E1
Cochrane high-quality SR/MA

How strongly each layer supports this effect

lower = less supportive
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
L1 ExamineGlobal benchmark
0.50
L5 Clinical bodiesAuthoritative stance
0.50
L11 AI re-checkIndependent read
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.472
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 1 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease
PMID: 12598816 2003 統合分析 n = 1,204
Finding: Across 21 pooled RCTs, ALCAR showed a significant but small advantage over placebo for the integrated summary effect (ES 0.201, 95% CI 0.107-0.295) and for CGI-CH (ES 0.32, 95% CI 0.18-0.47); benefit appeared by 3 months and increased over time, and ALCAR was well tolerated.
Effect size: ES 0.201 (integrated summary); ES 0.32 (CGI-CH) - both small
View on PubMed
Acetyl-L-carnitine for dementia (Cochrane systematic review)
PMID: 12804452 2003 Cochrane SR
Finding: Reviewers found a benefit on Clinical Global Impression at 12 and 24 weeks but no benefit on objective cognitive or functional outcomes; concluded there is no evidence to recommend routine clinical use of ALCAR for dementia.
🟢 High quality Effect size: No effect on objective cognitive measures; CGI benefit only
View on PubMed
Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update
PMID: 32408706 2020 系統性回顧
Finding: Results across trials are inconsistent; some studies show benefit in AD and MCI while others do not, and the role of ALCAR in dementia remains under debate. Authors conclude further studies with homogeneous samples and longitudinal assessment are needed before systematic clinical application.
Effect size: inconsistent; no robust pooled estimate
View on PubMed
L-carnitine for cognitive enhancement in people without cognitive impairment (Cochrane systematic review)
PMID: 28349514 2017 Cochrane SR n = 200
Finding: Only 2 small RCTs were eligible; evidence was very low quality and showed no effect of L-carnitine on reaction time, vigilance, immediate memory or delayed recall. Reviewers could not draw conclusions about efficacy or safety for cognitive enhancement in healthy people.
🟢 High quality Effect size: No measurable effect in healthy adults
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
NUTRIENT SUPPLEMENT [21 CFR 170.3(o) technical effect — substance: Carnitine / L-carnitine / Levocarnitine, CAS 541-15-1] source↗
L4b EU EFSA
Against
L4d TW TFDA / 衛福部
Neutral
形態屬膠囊狀、錠狀且標示有每日食用限量之食品,在每日食用量中,L-肉鹼(L-carnitine)總含量不得高於 2 公克。 source↗
L5a NIH Office of Dietary Supplements
Cautious
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-cognitive-function-INT-acetyl-l-carnitine-001 繁體中文版 →